These findings establish RFFL-targeting ASOs as first-in-class CFTR stabilizers and highlight their potential as a nucleic acid-based therapeutic strategy for CF caused by both common and rare CFTR mutations. This evidence concerns the gene CFTR and cystic fibrosis.